ATE516043T1 - Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden - Google Patents

Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden

Info

Publication number
ATE516043T1
ATE516043T1 AT06824316T AT06824316T ATE516043T1 AT E516043 T1 ATE516043 T1 AT E516043T1 AT 06824316 T AT06824316 T AT 06824316T AT 06824316 T AT06824316 T AT 06824316T AT E516043 T1 ATE516043 T1 AT E516043T1
Authority
AT
Austria
Prior art keywords
inhibitor
reperfusion injury
prevention
ischemic reperfusion
reperfusion
Prior art date
Application number
AT06824316T
Other languages
English (en)
Inventor
Maurice Mannesse
Johannes Henricus Nuijens
Frank Pieper
Simoni Maria Grazia De
Gijsbertus Johannes Ziere
Original Assignee
Pharming Intellectual Pty Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Pty Bv filed Critical Pharming Intellectual Pty Bv
Application granted granted Critical
Publication of ATE516043T1 publication Critical patent/ATE516043T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT06824316T 2005-12-21 2006-12-19 Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden ATE516043T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05112630 2005-12-21
US76094406P 2006-01-23 2006-01-23
PCT/NL2006/050321 WO2007073186A2 (en) 2005-12-21 2006-12-19 Use of c1 inhibitor for the prevention of ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
ATE516043T1 true ATE516043T1 (de) 2011-07-15

Family

ID=38016640

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06824316T ATE516043T1 (de) 2005-12-21 2006-12-19 Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden

Country Status (15)

Country Link
US (3) US8071532B2 (de)
EP (2) EP1965831B1 (de)
JP (2) JP5394748B2 (de)
KR (1) KR101508668B1 (de)
AT (1) ATE516043T1 (de)
AU (1) AU2006327989B2 (de)
CA (1) CA2632400C (de)
CY (2) CY1112452T1 (de)
DK (1) DK2380587T3 (de)
HR (2) HRP20110622T1 (de)
IL (2) IL192180A (de)
NZ (1) NZ568749A (de)
PL (2) PL2380587T3 (de)
SI (1) SI2380587T1 (de)
WO (1) WO2007073186A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu
EP2073898A1 (de) * 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Komplementhemmung für verbesserte nervenregeneration
JP5423266B2 (ja) * 2009-09-14 2014-02-19 富士電機株式会社 デジタル制御スイッチング電源装置
US9352016B2 (en) 2011-03-09 2016-05-31 Csl Behring Gmbh Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (de) * 2011-03-09 2012-09-12 CSL Behring GmbH Faktor XII-Hemmer zur Behandlung von schleichender Ischämie und Ischämie in anderen Organen
KR101956585B1 (ko) 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP6127063B2 (ja) * 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
EP3722320A3 (de) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-komplement-c1s-antikörper und verwendungen davon
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
ES2609070T3 (es) * 2013-02-28 2017-04-18 Csl Behring Gmbh Agente terapéutico para el embolismo de líquido amniótico
CN105188750A (zh) 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
CA2916399C (en) * 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
EP3708226A1 (de) * 2014-11-03 2020-09-16 Thrombolytic Science, LLC Verfahren und zusammensetzungen zur sicheren und wirksamen thrombolyse
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
US20190175683A1 (en) 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
IL273185B2 (en) 2017-09-15 2024-10-01 Cedars Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplantation subjects
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
CA3092163A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Treatment and prevention of pre-eclampsia
US20210380636A1 (en) 2018-10-17 2021-12-09 Csl Behring Gmbh Process for purifying c1-inh
EP3994165A1 (de) 2019-07-04 2022-05-11 CSL Behring GmbH Verfahren zur reinigung von c1-inh
KR102191500B1 (ko) 2020-03-30 2020-12-15 국립낙동강생물자원관 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
EP3895726A1 (de) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Verwendung von c1-esterase-inhibitoren zur behandlung von akuter atemnot im zusammenhang mit virusinfektionen
KR102217607B1 (ko) 2020-06-01 2021-02-18 국립낙동강생물자원관 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR102191452B1 (ko) 2020-06-30 2020-12-15 주식회사 에이치비헬스케어 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
WO2022109124A1 (en) 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
EP4366761A1 (de) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Verwendung von c1-esterase-inhibitor zur behandlung von symptomen im zusammenhang mit virusinfektionen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60030173T2 (de) 1999-05-14 2007-08-23 Steffen Thiel Neue Indikationen für Mannan-binding Lectin (MBL) zur Behandlung von immungeschwächten Patienten
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
JP2004100982A (ja) * 2002-09-05 2004-04-02 Denso Corp 熱交換器
AU2003301332B2 (en) 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
CN100431604C (zh) 2003-05-16 2008-11-12 法明知识产权股份有限公司 用于瞬时性治疗的具有短半衰期的c1抑制剂
PL2380587T3 (pl) 2005-12-21 2018-03-30 Pharming Intellectual Property B.V. Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Also Published As

Publication number Publication date
KR101508668B1 (ko) 2015-04-06
EP2380587B1 (de) 2017-10-25
US9211318B2 (en) 2015-12-15
CY1119818T1 (el) 2018-06-27
CA2632400C (en) 2016-06-07
PL2380587T3 (pl) 2018-03-30
HRP20171738T1 (hr) 2018-01-26
JP2009520815A (ja) 2009-05-28
EP1965831B1 (de) 2011-07-13
KR20080098001A (ko) 2008-11-06
US20130244941A1 (en) 2013-09-19
DK2380587T3 (en) 2017-12-04
PL1965831T3 (pl) 2011-12-30
JP5394748B2 (ja) 2014-01-22
AU2006327989B2 (en) 2012-06-07
IL228954A (en) 2016-10-31
SI2380587T1 (en) 2018-03-30
AU2006327989A1 (en) 2007-06-28
US8071532B2 (en) 2011-12-06
CA2632400A1 (en) 2007-06-28
JP2013126992A (ja) 2013-06-27
HRP20110622T1 (hr) 2011-09-30
WO2007073186A2 (en) 2007-06-28
US8415288B2 (en) 2013-04-09
WO2007073186A3 (en) 2007-08-09
IL192180A (en) 2013-10-31
US20080305993A1 (en) 2008-12-11
US20120088728A1 (en) 2012-04-12
EP1965831A2 (de) 2008-09-10
IL228954A0 (en) 2013-12-31
EP2380587A1 (de) 2011-10-26
CY1112452T1 (el) 2015-12-09
NZ568749A (en) 2011-05-27
IL192180A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
ATE516043T1 (de) Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
EA200602220A1 (ru) Новое применение пептидных соединений для лечения амиотрофического бокового склероза
NO20073783L (no) Pyrrolidininhibitorer for IAP
IS7753A (is) Beta-amínó heterósýklískir dípeptidýl peptíðasa hindrar til meðhöndlunar á, eða til að fyrirbyggja,sykursýki
NO20035603D0 (no) Fluorpyrrolidiner som dipeptidyl peptidase inhibitorer
BRPI0607017A2 (pt) métodos e composições para o tratamento de condições relacionadas ao snc
ATE524741T1 (de) Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
CO5570674A2 (es) Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos
SG159542A1 (en) Compositions against sars-coronavirus and uses thereof
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
NO20083032L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse
IN2014DN08578A (de)
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
SG151303A1 (en) New compounds for the inhibition of angiogenesis and use thereof
TW200720272A (en) Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
EA200401270A1 (ru) Тиазолидинкарбоксамидные производные как модуляторы рецептора простагландина f
DK2363130T3 (da) Kombination af HMG-CoA reduktaseinhibitorer atorvastatin eller simvastatin med en phosphodiesterase 4-inhibitor, såsom roflumilast til behandlingen af inflammatorisk pulmonære sygdomme
SI1973539T1 (sl) Uporaba benzokondenziranih heterocikličnih sulfamidnih derivatov za zdravljenje depresije
ATE439355T1 (de) 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren
DE602005010421D1 (de) Neue Cysteine Protease Hemmers und ihre therapeutische Anwendungen
WO2006102243A3 (en) Alpha ketoamide compounds as cysteine protease inhibitors
WO2010056877A3 (en) Haloalkyl containing compounds as cysteine protease inhibitors
ECSP003337A (es) Pirazolalquilamidas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1965831

Country of ref document: EP